Roivant Sciences Ltd.
For the period ended Mar 31, 2025. Filed May 29, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed May 29, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
| ITEM 2. | PROPERTIES |
|---|
Our principal executive offices are located at 7th Floor, 50 Broadway, London SW1H 0DB, United Kingdom. Our registered office is located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda.
Our subsidiary Roivant Sciences, Inc. (“RSI”) subleases 83,340 square feet of office space located in New York, New York, pursuant to a sublease agreement that expires in October 2032. In September 2024, RSI entered into a new lease agreement (the “RSI Lease Agreement”) with One Penn Plaza LLC for office space in New York, New York to serve as the future U.S. corporate headquarters of RSI. The RSI Lease Agreement commenced in December 2024 and will expire in August 2041. The lease contains an option to early terminate in August 2036 and an option to extend the term for one additional period of five years or 10 years at then-market rates in August 2041. Certain of our subsidiaries and affiliates also lease office space in New York, New York and Basel, Switzerland. We do not own any properties.
We believe that our and our subsidiaries’ leased facilities are in good condition and are well maintained and that our current arrangements will be sufficient to meet our needs for the foreseeable future and that any required additional space will be available on commercially reasonable terms to meet space requirements if they arise.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.